Navigation Links
New personalized treatment options for cancer
Date:12/19/2011

A new cancer research centre established at the University of Adelaide will focus on treatment options tailored to the individual, taking into account DNA and genetic variations between people.

The Centre for Personalised Cancer Medicine brings together a team of world-leading researchers with strengths in blood cancers and solid tumours, particularly breast, lung, sarcomas and melanoma.

Headed by Professor David Callen, the team will use tumour profiling and animal and cellular models to develop new drugs that target particular molecular changes in individual cancer patients.

"This centre reflects the trend towards a new, individualised approach to cancer medicine, taking into account genetic variations between people and their reaction to specific drugs," Professor Callen says.

"We will focus on improving the outcomes for cancer patients at all levels, from prevention through to treatment, survival, rehabilitation and palliative care, exploring novel and innovative approaches to cancer research.

"The big thrust at the moment is DNA sequencing. While it is still in the developmental stage, there are enormous resources being poured into this overseas and it looks like we will follow this lead in Australia."

The centre is already making headway in some areas, particularly in the treatment of sarcomas − rare malignant tumours which disproportionately affect young people and have a high mortality rate.

Dr Paul Neilsen, who oversees the Sarcoma Research Group, is collaborating with Royal Adelaide Hospital surgeon A/Prof Susan Neuhaus to trial new drugs on individual patient's tumours in a laboratory setting. "Currently these patients are treated with chemotherapy and radiotherapy but their outcomes are very poor and have not improved in the past decade," Dr Neilsen says.

"We have identified weak points in these tumours and are targeting them with new agents. The next step is to support pre-clinical trials in Australia."

Dr Neilsen lost his 18-year-old brother to Ewing's Sarcoma a malignant bone tumour which occurs most frequently in male teenagers and has a mortality rate of 40%, but increases to 90% for metastatic or recurrent disease.

Adelaide man John Marshall was a lot older 41 years of age when he was diagnosed with Ewing's Sarcoma in July 2010, undergoing surgery to remove the tumour, along with 12 months of chemotherapy.

"The diagnosis floored me. I was a fit, happy, healthy guy who had never smoked, ate a healthy diet and worked out regularly. How could this happen to me?"

While Mr Marshall has been given the all clear following his treatment, he is keen to support sarcoma research being undertaken at the Centre for Cancer Personalised Medicine and the Royal Adelaide Hospital. He is planning a sponsored cycle ride through the French Alps in September 2102.


'/>"/>
Contact: Professor David Callen
david.callen@adelaide.edu.au
61-882-223-145
University of Adelaide
Source:Eurekalert

Related medicine news :

1. New book by University of Louisville professor enables reader to develop personalized anti-depression plan
2. Northwestern to explore personalized medicine for scleroderma
3. Tumor-targeting compound points the way to new personalized cancer treatments
4. New and varied imaging techniques facilitate personalized medicine
5. Matching targeted therapies to tumors specific gene mutations key to personalized cancer treatment
6. Breast milk may provide a personalized screen of breast cancer risk
7. WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves
8. IU Personalized Medicine Institute to develop targeted and individualized treatments
9. Tufts University calls for moderate approach to teaching personalized genomic testing
10. Personalized molecular therapy shows promising results for people with advanced lung cancer
11. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... Crossover Symmetry , an evidence based ... lifestyle company that provides Human Performance Training and education to tactical athletes. Together ... military officers and others in service through the development and conditioning of overall ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical ... Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual ... healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, share ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a ... Care of Utah (APCUT) and has appointed Rex Wheeler as its new Director of ... for our agency and our ability to provide quality care to the community,” said ...
(Date:4/21/2017)... ... , ... During April 21-23, Super-Sod will join the vendor market of the ... everyone — from the avid gardener to the landscape admirer — during the three-day ... in a grand venue, and we are certainly looking forward to participating in this ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted ... of bed bug infestations over the 5-year period. In 2015 10% or US$750 million ... of bed bug infested properties. , The health and economic consequences of bed ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
Breaking Medicine Technology: